While it’s true that fenbendazole has anti-tumor effects in cell cultures and in animal models, there’s no evidence that it can cure cancer in human patients. Tippens’ anecdotal experience isn’t generalizable to other cancer patients, and there are other possible explanations for his remission that haven’t been accounted for. To arrive at more reliable conclusions, randomized controlled trials involving large numbers of patients need to be performed.
In one study, researchers administered fenbendazole to mice with tumors. After 12 days, they measured and weighed the animals’ tumors and found that they were smaller in mice receiving fenbendazole than in those not receiving the drug. The authors speculated that fenbendazole inhibits tumor growth by causing apoptosis of cancer cells.
Another study, also conducted in a mouse model, found that fenbendazole suppressed tumor growth after radiation. It was also found that the drug slows down the accumulation of new DNA in cells, preventing them from becoming malignant. In addition, the drug inhibits the RAS-related signaling pathway in cells with a KRAS mutation.
A third study found that fenbendazole reduces glucose uptake by cancer cells, which is essential for their survival. In addition, it prevents the synthesis of new proteins that support tumor growth. The findings suggest that fenbendazole is a promising candidate for use as an anti-cancer agent. Similar results were observed in other studies involving human cancer cells and mice with genetically engineered lung adenocarcinoma tumors. The findings suggest that fenbendazole may be useful in treating different types of cancer, including those with a mutation in the p53 gene. fenbendazole cancer